SoftBank has exited the electronic health record platform through a $32.7m acquisition by medical school operator Afya.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Codiak – based on research at Gothenburg and MD Anderson Cancer Center – has succeeded in going public after previously cancelling plans.

The federal development board for Southern Ontario has injected $5m to accelerate the growth potential of TIAP's early-stage health sciences portfolio.

Five years after being co-founded by UCL researchers, Ori Biotech has brought its overall funding to $41m.

Novo-backed congenital adrenal hyperplasia drug developer Spruce Biosciences has added approximately $14m to close its initial public offering.

The personalised medicine technology provider hiked its overall funding to $115m, with Cardinal Health, McKesson Ventures and Novartis all backing a series C extension.

The protein drug developer has now secured more than $195m in total, its earlier backers including GlaxoSmithKline, Pfizer, Eli Lilly and Schrödinger.

Cancer drug developer ImmuneOnco has caught the attention of Eli Lilly's Asia-focused vehicle and will put the series B proceeds toward clinical trials.

Alphabet subsidiary GV led a $16.5m series A round for the healthcare revenue management startup that followed a $6m round last year.